- hyperoxaluria. It is an LDHA-directed
small interfering RNA
developed by
Dicerna Pharmaceuticals. The most
common side
effects include injection site reactions...
-
Technologies for $1.35 billion. In
November 2021, Novo
announced it
would acquire Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3
billion ($38.25 per...
- RNAi
therapy for humans.
Alnylam Pharmaceuticals,
Sirna Therapeutics and
Dicerna Pharmaceuticals are few of the
companies still working on
bringing RNAi...
- payloads,
which are
necessarily non-viral
delivery problems. Alnylam,
Dicerna Pharmaceuticals, and
Ionis Pharmaceuticals focus on
delivery of
siRNA (antisense...
-
developed by
pharmaceutical companies such as
Arrowhead Pharmaceuticals,
Dicerna,
Alnylam Pharmaceuticals, Amgen, and Sylentis.
These medications cover...
- and saw
forward to
initial public offering a
number of firms,
including Dicerna Pharmaceuticals and
Clovis Oncology. The firm has also
provided funding...
